TrialJournal of neurology2023

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).

Maryam Oskoui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.